Immunogenicity, safety, and reactogenicity of heterologous C

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Porton Down , Wiltshire , United Kingdom , Berkshire , United Kingdom General , Chad , Canada , Wuhan , Hubei , China , Oxford Immunotec , Oxford Immunotec Abingdon , Nat Protoc , University Of Oxford , United Kingdom Health Security Agency , South Central Berkshire Research Ethics Committee , National Health Service , Coalition For Epidemic Preparedness Innovations , Regulatory Agency , Pfizer , National Institute For Health Research , Astrazeneca , United Kingdom Vaccine Task , Public Health England , Pearson , Kingdom Vaccine Task Force , Epidemic Preparedness Innovations , National Institute , Roche Diagnostics , T Cell Xtend ,